C-Terminal Fragment, Aβ32-37, Analogues Protect Against Aβ Aggregation-Induced Toxicity

ACS Chemical Neuroscience

Volumn 7, Issue 5, 2016, Pages 615-623

  Bansal, Sunil ^a   Maurya, Indresh Kumar ^b   Yadav, Nitin ^c   Thota, Chaitanya Kumar ^c   Kumar, Vinod ^a   Tikoo, Kulbhushan ^a   Chauhan, Virander Singh ^c   Jain, Rahul ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b PANJAB UNIVERSITY   (India)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Alzheimer's disease; A aggregation; hexapeptide; MTT; TEM; ThT fluorescence assay

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[32-37]; HEXAPEPTIDE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY ASSAY; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MORPHOLOGY; MTT ASSAY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SECONDARY STRUCTURE; RAT; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PC12 CELL LINE; PHYSIOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL SURVIVAL; PC12 CELLS; PEPTIDE FRAGMENTS; PROTEIN AGGREGATES; RATS;

EID: 84969802160     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.6b00006     Document Type: Article

References (41)

1. Stelzmann, R. A., Schnitzlein, H. N., and Murtagh, F. R. (1995) An English translation of Alzheimers 1907 paper, über eine eigenartige erkankung der hirnrinde Clin. Anat. 8, 429-431 10.1002/ca.980080612
2. Prince, M., Albanese, E., Guerchet, M., and Prina, M. (2014) Dementia and risk reduction: An analysis of protective and modifiable factors, Alzheimers Disease International, London, http://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf.
3. Selkoe, D. J. (1997) Alzheimers Disease: genotypes, phenotype, and treatments Science 275, 630-631 10.1126/science.275.5300.630
4. Haass, C. and Selkoe, D. J. (1993) Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide Cell 75, 1039-1042 10.1016/0092-8674(93)90312-E
5. Eisenberg, D. and Jucker, M. (2012) The amyloid state of proteins in human diseases Cell 148, 1188-1203 10.1016/j.cell.2012.02.022
6. Roberson, E. D. and Mucke, L. (2006) 100 years and counting: prospects for defeating Alzheimers disease Science 314, 781-784 10.1126/science.1132813
7. Vellas, B., Sol, O., Snyder, P., Ousset, P., Haddad, R., Maurin, M., Lemarié, J.-C., Désiré, L., and Pando, M. (2011) EHT0202 in Alzheimers disease: A 3-month, randomized, placebo-controlled, double-blind study Curr. Alzheimer Res. 8, 203-212 10.2174/156720511795256053
8. Merck.ClinicalTrials.gov [website on the Internet] Bethesda, MD: US national library of medicine; 2013. [Accessed November 22, 2013]. Efficacy and safety trial of MK-8931 in participants with prodromal Alzheimers disease (MK-8931-019) (APECS) [updated November 19, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01953601?term=MK-8931&rank=3. NLM identifier: NCT01953601.
9. Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., and Aisen, P. S. et al. 2013, A phase III trial of semagacestat for treatment of Alzheimers disease N. Engl. J. Med. 369, 341-350 10.1056/NEJMoa1210951
10. Wilcock, G. K., Black, S. E., Balch, A. H., Amato, D. A., Beelen, A. P., Schneider, L. S., Green, R. C., Swabb, E. A., and Zavitz, K. H. (2009) Safety and efficacy of tarenflurbil in subjects with mild Alzheimers disease: Results from an 18-month international multi-center phase III trial Alzheimer's Dementia 5, 86 10.1016/j.jalz.2009.05.220
11. Coric, V., Salloway, S., van Dyck, C. V., Kerselaers, W., Kaplita, S., Curtis, C., Ross, J., Richter, R. W., Andreasen, N., Brody, M., Sharma, S. K., Cedarbaum, J. M., and Berman, R. (2013) A phase II study of the ϵ-secretase inhibitor avagacestat (BMS-708163) in predementia Alzheimers disease Alzheimer's Dementia 9, 283 10.1016/j.jalz.2013.05.569
12. 1-42 immunization in Alzheimers disease: Follow-up of a randomised, placebo-controlled phase I trial Lancet 372, 216-223 10.1016/S0140-6736(08)61075-2
13. Blennow, K., Zetterberg, H., Rinne, J. O., Salloway, S., Wei, J., Black, R., Grundman, M., and Liu, E. (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild-to-moderate Alzheimer disease Arch. Neurol. 69, 1002-1010 10.1001/archneurol.2012.90
14. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q. X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R. E., and Masters, C. L. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: A pilot phase II clinical trial Arch. Neurol. 60, 1685-1691 10.1001/archneur.60.12.1685
15. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., Wilson, J., and Ritchie, C. W. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimers disease: A phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7, 779-786 10.1016/S1474-4422(08)70167-4
16. Safety and efficacy study evaluating TRx0237 in subjects with mild-to-moderate Alzheimers disease. https://www.clinicaltrials.gov/ct2/show/NCT01689233.
17. Gozes, I., Morimoto, B. H., Tiong, J., Fox, A., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P., Aisen, P. S., Matsuoka, Y., Dyck, C. H., and Thal, L. (2005) NAP: Research and development of a peptide derived from activity-dependant neuroprotective protein (ADNP) CNS Drug Rev. 11, 353-368 10.1111/j.1527-3458.2005.tb00053.x
18. Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A., and Arancio, O. (2008) Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus J. Neurosci. 28, 14537-14545 10.1523/JNEUROSCI.2692-08.2008
19. Yang, F. S., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., and Cole, G. M. (2005) Curcumin inhibits formation of amyloid-β oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280, 5892-5901 10.1074/jbc.M404751200
20. Nakagami, Y., Nishimura, S., Murasugi, T., Kaneko, I., Meguro, M., Marumoto, S., Kogen, H., Koyama, K., and Oda, T. (2002) A novel β-sheet breaker, RS-0406, reverses amyloid β-induced cytotoxicity and impairment of long-term potentiation in vitro Br. J. Pharmacol. 137, 676-682 10.1038/sj.bjp.0704911
21. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67, 27-37 10.1111/j.1747-0285.2005.00318.x
22. Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., and Sampalis, J. (2011) Tramiprosate in mild-to-moderate Alzheimers disease- A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch. Med. Sci. 1, 102-111 10.5114/aoms.2011.20612
23. Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., Crans, G., Liang, E., Quinn, G., Bairu, M., Pastrak, A., and Cedarbaum, J. D. (2011) A phase II randomized trial of ELND005, scyllo-inositol, in mild-to-moderate Alzheimer disease Neurology 77, 1253-1262 10.1212/WNL.0b013e3182309fa5
24. Mahler, A., Mandel, S., Lorenz, M., Ruegg, U., Wanker, E. E., Boschmann, M., and Paul, F. (2013) Epigallocatechin-3-gallate: A useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA Journal 4, 5 10.1186/1878-5085-4-5
25. Kokkoni, N., Stott, K., Amijee, H., Mason, J. M., and Doig, A. J. (2006) N-Methylated peptide inhibitors of β-amyloid aggregation and toxicity. Optimization of the inhibitor structure Biochemistry 45, 9906-9918 10.1021/bi060837s
26. Grillo-Bosch, D., Carulla, N., Cruz, M., Sánchez, L., Pujol-Pina, R., Madurga, S., Rabanal, F., and Giralt, E. (2009) Retro-enantio N-methylated peptides as-amyloid aggregation inhibitors ChemMedChem 4, 1488-1494 10.1002/cmdc.200900191
27. 1-40 fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues Biochemistry 40, 8237-8245 10.1021/bi002416v
28. Matharu, B., El-Agnaf, O., Razvi, A., and Austen, B. M. (2010) Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimers disease Peptides 31, 1866-1872 10.1016/j.peptides.2010.06.033
29. Chacon, M. A., Barria, M. I., Soto, C., and Inestrosa, N. C. (2004) β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits Mol. Psychiatry 9, 953-961 10.1038/sj.mp.4001516
30. 2 neutralizes Aβ-induced memory impairment & toxicity J. Alzheimer's Dis. 19, 991-1005
31. Jhee, S. S. (2003) Single dose escalation study of PPI-1019, an Aβ aggregation inhibitor, New Clinical Drug Evaluation Unit, Boca Raton, FL.
32. 1-42-induced neurotoxicity Proc. Natl. Acad. Sci. U. S. A. 105, 14175-14180 10.1073/pnas.0807163105
33. Pratim Bose, P., Chatterjee, U., Nerelius, C., Govender, T., Norström, T., Gogoll, A., Sandegren, A., Göthelid, E., Johansson, J., and Arvidsson, P. I. (2009) Poly-N-methylated amyloid β-peptide (Aβ) C-terminal fragments reduce Aβ toxicity in vitro and in Drosophila melanogaster J. Med. Chem. 52, 8002-8009 10.1021/jm901092h
34. Jarrett, J. T., Berger, E. P., and Lansbury, P. T., Jr (1993) The carboxy terminus of the amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimers disease? Biochemistry 32, 4693-4697 10.1021/bi00069a001
35. Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C. L., and Beyreuther, K. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimers disease Aβ peptides J. Mol. Biol. 228, 460-473 10.1016/0022-2836(92)90835-8
36. Shearman, M. S., Ragan, C. I., and Iversen, L. L. (1994) Inhibition of PC-12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death Proc. Natl. Acad. Sci. U. S. A. 91, 1470-1474 10.1073/pnas.91.4.1470
37. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays J. Immunol. Methods 65, 55-56 10.1016/0022-1759(83)90303-4
38. Liu, Y., Peterson, D. A., Kimura, H., and Schubert, D. (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction J. Neurochem. 69, 581-593 10.1046/j.1471-4159.1997.69020581.x
39. LeVine, H. (1993) Thioflavine T interaction with synthetic Alzheimers disease β-amyloid peptides: Detection of amyloid aggregation in solution Protein Sci. 2, 404-410 10.1002/pro.5560020312
40. Alder, A. J., Greenfield, N. J., and Fasman, G. D. (1973) Circular dichroism and optical rotatory dispersion of proteins and polypeptides Methods Enzymol. 27, 675-735 10.1016/S0076-6879(73)27030-1
41. Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W. M., Mattson, M. P., and Tycko, R. (2005) Self-propagating, molecular-level polymorphism in Alzheimers β-amyloid fibrils Science 307, 262-265 10.1126/science.1105850